Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2024-02-02 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-02-02 English
Regulatory Filings 2024
Regulatory Filings Classification · 90% confidence The provided document text appears to be heavily encoded or corrupted, containing no readable or meaningful financial, corporate, or regulatory information. There are no identifiable keywords, regulatory references, report titles, fiscal periods, or any content that would allow classification into a specific filing category. Given the lack of discernible content, the document cannot be classified as a substantive report or announcement. According to the fallback rule, such documents should be classified as Regulatory Filings (RNS). The document length is sufficient to exclude it being a mere report publication announcement, but the content is unreadable and does not fit any other category.
2024-01-30 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 25, 2024, reporting the submission of matters to a vote of security holders at a special meeting. It details the final voting results on several proposals related to stock issuance, amendments to the certificate of incorporation, and equity incentive plans. The document includes explicit voting results and references a press release attached as an exhibit. The content is focused on the official results of shareholder votes at a meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full annual or quarterly report, nor is it a proxy solicitation or management discussion. It is a current report specifically reporting voting outcomes, fitting the DVA classification with high confidence.
2024-01-25 English
FORM SC 13D/A10
Major Shareholding Notification
2024-01-24 English
FORM SC 13D/A9
Major Shareholding Notification
2024-01-24 English
FORM SC 13D/A8
Major Shareholding Notification
2024-01-24 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.